Private Equity Snatches PRA for $1.3B

By Zachary Brennan contact

- Last updated on GMT

Private Equity Snatches PRA for $1.3B

Related tags: Private equity

Kohlberg Kravis Roberts (KKR) has purchased PRA International for $1.3B, which is about $500M more than previous private equity owner Genstar paid in 2007.

Over the weekend KKR acquired us from Genstar, allowing us to accelerate growth and step into the big leagues​,” Colin Shannon, president and CEO of PRA, told Outsourcing-Pharma.com at the announcement of the deal at DIA’s 49th​ annual meeting in Boston on Monday.

KKR’s purchase came after intense bidding from two other private equity firms that Shannon refused to name, but which Reuters​ previously reported as Warburg Pincus and Cinven.

Shannon noted the “close finish​” with the other two private equity firms in his announcement. In terms of how KKR will influence PRA’s decisions moving forward, Shannon told us, “I run the company​,” adding that they will offer some strategic influence, but “ultimately I make the choices​,” as it was with the company’s previous private equity owner Genstar​.

They’re there to help us and not interfere​,” Shannon added, noting KKR’s $78B in assets will help PRA find ways to build and improve.

PRA initially filed a confidential S-1​ with the US SEC to go public in May, but industry insiders told us​ last week that was a ploy to attract private equity interest.

Shannon said the decision to not take the company public was a strategic one related to market awareness and the company’s scale. He added that PRA will look into an IPO again in a few years, noting the success of Quintiles’ recent IPO. PRA said that the acquisition will not affect the way the company is run or the executive management.

The price of the acquisition was first reported by the New York Times​ on Monday. The deal is expected to close in the third quarter of this year, Shannon said.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us

Products

View more

Webinars